# TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

> **NCT00543725** · PHASE3 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 680 (actual)

## Conditions studied

- HIV Infections
- HIV-1

## Interventions

- **DRUG:** TMC278
- **DRUG:** efavirenz

## Key facts

- **NCT ID:** NCT00543725
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2010-01
- **Final completion:** 2012-02
- **Target enrollment:** 680 (ACTUAL)
- **Last updated:** 2016-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00543725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00543725, "TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00543725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*